A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

To evaluate the degree and sequence of immunologic enhancement and the cellular resistance to certain infections after a single dose of atvogen (ampligen). In addition, the relationship between activation of immune cells and biochemical markers of that activation will be studied. Treatment of patients with HIV infection must address both the primary viral infection and the subsequent immune deficiency, which is the primary cause of mortality in A... more

Medical trial

ClinicalTrials.gov Identifier:

  • NCT00001000

Type of trial:

Expected total enrollment:

  • 20

Eligibile genders:

Minimum age for eligibility:

  • 18

Maximum age for eligibility:

  • 45

Eligibility inclusion criteria:

  • Healthy

Eligibility exclusion criteria:

  • Smokers.
  • Volunteers who have ingested alcohol 48 hours prior to the study.
  • Volunteers with clinically apparent viral disease or other illnesses, including allergies, within 2 weeks prior to the study or conditions which predispose them to chronic immune stimulation.

Diseases:

Treatment being tested:

top ↑
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution